Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Neurochem Int ; 53(6-8): 296-308, 2008 Dec.
Article in English | MEDLINE | ID: mdl-18805448

ABSTRACT

Sodium-dependent glutamate uptake is essential for limiting excitotoxicity, and dysregulation of this process has been implicated in a wide array of neurological disorders. The majority of forebrain glutamate uptake is mediated by the astroglial glutamate transporter, GLT-1. We and others have shown that this transporter undergoes endocytosis and degradation in response to activation of protein kinase C (PKC), however, the mechanisms involved remain unclear. In the current study, transfected C6 glioma cells or primary cortical cultures were used to show that PKC activation results in incorporation of ubiquitin into GLT-1 immunoprecipitates. Mutation of all 11 lysine residues in the amino and carboxyl-terminal domains to arginine (11R) abolished this signal. Selective mutation of the seven lysine residues in the carboxyl terminus (C7K-R) did not eliminate ubiquitination, but it completely blocked PKC-dependent internalization and degradation. Two families of variants of GLT-1 were prepared with various lysine residues mutated to arginine. Analyses of these constructs indicated that redundant lysine residues in the carboxyl terminus were sufficient for the appearance of ubiquitinated product and degradation of GLT-1. Together these data define a novel mechanism by which the predominant forebrain glutamate transporter can be rapidly targeted for degradation.


Subject(s)
Astrocytes/metabolism , Brain/metabolism , Excitatory Amino Acid Transporter 2/metabolism , Glutamic Acid/metabolism , Ubiquitin/metabolism , Ubiquitination/physiology , Amino Acid Sequence/genetics , Animals , Cell Line, Tumor , Cerebral Cortex/metabolism , Down-Regulation/genetics , Endocytosis/physiology , Excitatory Amino Acid Transporter 2/chemistry , Excitatory Amino Acid Transporter 2/genetics , Lysine/metabolism , Mutation/genetics , Protein Kinase C/metabolism , Protein Structure, Tertiary/genetics , Protein Transport/physiology , Rats
2.
J Biol Chem ; 282(41): 29855-65, 2007 Oct 12.
Article in English | MEDLINE | ID: mdl-17715130

ABSTRACT

The sodium-dependent glutamate transporter, excitatory amino acid carrier 1 (EAAC1), has been implicated in the regulation of excitatory signaling and prevention of cell death in the nervous system. There is evidence that EAAC1 constitutively cycles on and off the plasma membrane and that under steady state conditions up to 80% of the transporter is intracellular. As is observed with other neurotransmitter transporters, the activity of EAAC1 is regulated by a variety of molecules, and some of these effects are associated with redistribution of EAAC1 on and off the plasma membrane. In the present study we tested the hypothesis that a structural component of lipid rafts, caveolin-1 (Cav-1), may participate in EAAC1 trafficking. Using C6 glioma cells as a model system, co-expression of Cav-1 S80E (a dominant-negative variant) or small interfering RNA-mediated knock-down of caveolin-1 reduced cell surface expression of myc epitope-tagged EAAC1 or endogenous EAAC1, respectively. Cav-1 S80E slowed the constitutive delivery and endocytosis of myc-EAAC1. In primary cultures derived from caveolin-1 knock-out mice, a similar reduction in delivery and internalization of endogenous EAAC1 was observed. We also found that caveolin-1, caveolin-2, or Cav-1 S80E formed immunoprecipitable complexes with EAAC1 in C6 glioma and/or transfected HEK cells. Together, these data provide strong evidence that caveolin-1 contributes to the trafficking of EAAC1 on and off the plasma membrane and that these effects are associated with formation of EAAC1-caveolin complexes.


Subject(s)
Amino Acid Transport System X-AG/metabolism , Caveolin 1/biosynthesis , Caveolin 1/physiology , Excitatory Amino Acid Transporter 3/metabolism , Animals , Astrocytes/metabolism , Cell Line, Tumor , Cell Membrane/metabolism , Endocytosis , Kinetics , Membrane Microdomains/metabolism , Mice , Mice, Knockout , Neurotransmitter Agents/metabolism , Rats
3.
Neuropharmacology ; 49(6): 872-82, 2005 Nov.
Article in English | MEDLINE | ID: mdl-16182322

ABSTRACT

Previously we have shown that platelet-derived growth factor (PDGF) rapidly increases the activity of the neuronal glutamate transporter, EAAC1. This increase in activity is associated with a rapid (within minutes) redistribution of transporter from a subcellular compartment to the plasma membrane and is blocked by inhibitors of phosphatidylinositol 3-kinase (PI3K). Similar effects of PI3K inhibitors have been observed for insulin-dependent up-regulation of the GLUT4 subtype of glucose transporter. Although GLUT4 regulation also depends on the serine-threonine kinase (Akt/protein kinase B), a downstream target of PI3K, the downstream effectors responsible of PDGF-dependent regulation of EAAC1 have not been identified. In the present study, PDGF increased the level of Akt phosphorylation (Ser 473) in C6 glioma cells, a cell line that has been used to study regulated trafficking of endogenous EAAC1. Two inhibitors of PI3K blocked this effect. In transient transfection studies, a dominant negative mutant of Akt-1 blocked PDGF-induced redistribution of epitope-tagged EAAC1 (myc-EAAC1). Conversely, constitutively active Akt-1 (CA Akt-1) increased the cell surface expression of myc-EAAC1. A lentiviral vector engineered to express CA Akt-1 increased Akt activation, cell surface expression of endogenous EAAC1, and Na(+)-dependent glutamate transport activity. Together, these studies suggest that Akt is required for PDGF-induced regulation of EAAC1.


Subject(s)
Excitatory Amino Acid Transporter 3/metabolism , Gene Expression/physiology , Platelet-Derived Growth Factor/metabolism , Proto-Oncogene Proteins c-akt/metabolism , Animals , Biological Transport/drug effects , Biological Transport/physiology , Biotinylation/methods , Blotting, Western/methods , Cell Line, Tumor , Cloning, Molecular/methods , Drug Interactions , Enzyme Inhibitors/pharmacology , Gene Expression/drug effects , Genetic Engineering/methods , Glioma , Glutamic Acid/metabolism , Mice , Proto-Oncogene Proteins c-myc/metabolism , Serine/metabolism , Sodium/metabolism , Transfection/methods
SELECTION OF CITATIONS
SEARCH DETAIL
...